复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02696 复宏汉霖

已收盘 02-23 16:08:03

69.400

-2.850

-3.94%

最高73.000	最低69.000	成交量48.36万
今开73.000	昨收72.250	日振幅5.54%
总市值376.84亿	流通市值240.18亿	总股本5.43亿
成交额3,387万	换手率0.14%	流通股本3.46亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02696","market":"HK","secType":"STK","nameCN":"复宏汉霖","latestPrice":69.4,"timestamp":1771834083008,"preClose":72.25,"halted":0,"volume":483600,"delay":0,"changeRate":-0.039446366782006845,"floatShares":346074397,"shares":543000000,"eps":1.509618,"marketStatus":"已收盘","change":-2.85,"latestTime":"02-23 16:08:03","open":73,"high":73,"low":69,"amount":33871599,"amplitude":0.055363,"askPrice":69.45,"askSize":100,"bidPrice":69.15,"bidSize":4300,"shortable":3,"etf":0,"ttmEps":1.661924,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1771896600000},"marketStatusCode":5,"adr":0,"listingDate":1569340800000,"exchange":"SEHK","adjPreClose":72.25,"openAndCloseTimeList":[[1771810200000,1771819200000],[1771822800000,1771833600000]],"volumeRatio":0.277461,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02696/wiki","defaultTab":"wiki","newsList":[{"id":"2612436735","title":"每日卖空追踪 | 复宏汉霖 02月16日卖空量成交2.74万股，卖空比例为16.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2612436735","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612436735?lang=zh_cn&edition=full","pubTime":"2026-02-16 16:30","pubTimestamp":1771230629,"startTime":"0","endTime":"0","summary":"复宏汉霖北京时间02月16日，涨0.21%，卖空量成交2.74万股，较上一交易日增加106.02%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260216163411a700dfa3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260216163411a700dfa3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000306701.USD","HK0000320223.HKD","02696","HK0000165453.HKD","HK0000306685.HKD","BK1161","HK0000320264.USD"],"gpt_icon":0},{"id":"2612436755","title":"复宏汉霖02月16日主力净流入78.0万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2612436755","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612436755?lang=zh_cn&edition=full","pubTime":"2026-02-16 16:15","pubTimestamp":1771229750,"startTime":"0","endTime":"0","summary":"02月16日, 复宏汉霖股价涨0.21%，报收70.50元，成交金额1132.7万元，换手率0.05%，振幅2.99%，量比0.05。复宏汉霖今日主力资金净流入78.0万元，上一交易日主力净流出97.8万元。该股近5个交易日上涨5.15%，主力资金累计净流入2990.1万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流出411.7万元，其中净流出天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260216161853a4a9ee5f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260216161853a4a9ee5f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000306701.USD","02696","HK0000165453.HKD","HK0000320223.HKD","BK1161","HK0000306685.HKD","HK0000320264.USD"],"gpt_icon":0},{"id":"2611103848","title":"复宏汉霖(02696)：HLX15-SC (重组抗CD38全人单克隆抗体注射液-皮下注射)用于多发性骨髓瘤治疗的1期临床试验申请获美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2611103848","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611103848?lang=zh_cn&edition=full","pubTime":"2026-02-16 12:36","pubTimestamp":1771216560,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 发布公告，近日，本公司自主研发的HLX15-SC 用于多发性骨髓瘤治疗的1期临床试验申请获美国食品药品管理局批准。HLX15是本公司自主研发的达雷妥尤单抗生物类似药，拟用于多发性骨髓瘤等治疗。2024年6月，HLX15-IV在中国男性健康受试者中开展的 1期临床研究已成功完成。2026年2月，HLX15-SC用于多发性骨髓瘤治疗的 1期临床试验申请获国家药品监督管理局批准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1405675.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"复宏汉霖(02696)：HLX15-SC (重组抗CD38全人单克隆抗体注射液-皮下注射)用于多发性骨髓瘤治疗的1期临床试验申请获美国FDA批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000165453.HKD","HK0000306685.HKD","HK0000320264.USD","HK0000306701.USD","02696","BK1161","HK0000320223.HKD"],"gpt_icon":0},{"id":"2611153153","title":"每日卖空追踪 | 复宏汉霖 02月13日卖空量成交4900股，卖空比例为0.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2611153153","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611153153?lang=zh_cn&edition=full","pubTime":"2026-02-13 16:30","pubTimestamp":1770971435,"startTime":"0","endTime":"0","summary":"复宏汉霖北京时间02月13日，跌2.22%，卖空量成交4900股，较上一交易日减少89.62%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213163522a49ffa9d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213163522a49ffa9d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000306701.USD","HK0000306685.HKD","HK0000320264.USD","02696","HK0000320223.HKD","BK1161","HK0000165453.HKD"],"gpt_icon":0},{"id":"2611148153","title":"复宏汉霖02月13日主力净流出97.8万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2611148153","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611148153?lang=zh_cn&edition=full","pubTime":"2026-02-13 16:15","pubTimestamp":1770970546,"startTime":"0","endTime":"0","summary":"02月13日, 复宏汉霖股价跌2.22%，报收70.35元，成交金额6214.3万元，换手率0.26%，振幅4.93%，量比0.26。复宏汉霖今日主力资金净流出97.8万元，上一交易日主力净流入69.1万元。该股近5个交易日上涨9.72%，主力资金累计净流入3088.0万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流出378.4万元，其中净流出天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213161932a6f6d402&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213161932a6f6d402&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000306701.USD","HK0000306685.HKD","HK0000165453.HKD","HK0000320223.HKD","BK1161","HK0000320264.USD","02696"],"gpt_icon":0},{"id":"2611976680","title":"复星医药控股子公司药品获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2611976680","media":"格隆汇资讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611976680?lang=zh_cn&edition=full","pubTime":"2026-02-12 17:54","pubTimestamp":1770890043,"startTime":"0","endTime":"0","summary":"格隆汇2月12日丨复星医药公告，近日，上海复星医药(集团)股份有限公司控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司收到国家药品监督管理局关于同意HLX15-SC用于多发性骨髓瘤治疗开展Ⅰ期临床试验的批准。复宏汉霖拟于条件具备后在中国境内开展该药品的相关临床研究。2024年6月，在中国男性健康受试者中开展的HLX15-IVⅠ期临床研究已完成。根据IQVIAMIDAS1最新数据，2024年，达雷妥尤单抗制剂于全球范围的销售额约128.82亿美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212175415a6f2df4f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212175415a6f2df4f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000165453.HKD","02196","BK1191","BK1593","HK0000306685.HKD","HK0000306701.USD","HK0000320264.USD","02696","BK1161","BK1515","HK0000320223.HKD"],"gpt_icon":0},{"id":"2610945272","title":"复宏汉霖(02696)：HLX15-SC用于多发性骨髓瘤治疗的1期临床试验申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2610945272","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610945272?lang=zh_cn&edition=full","pubTime":"2026-02-12 17:06","pubTimestamp":1770887210,"startTime":"0","endTime":"0","summary":"金吾财讯 | 复宏汉霖(02696)公告公布，近日，公司自主研发的HLX15-SC（重组抗CD38全人单克隆抗体注射液－皮下注射）（“HLX15-SC”）用于多发性骨髓瘤治疗的1期临床试验申请(IND)获国家药品监督管理局(NMPA)批准。HLX15（重组抗CD38全人单克隆抗体）是公司自主研发的达雷妥尤单抗生物类似药，拟用于多发性骨髓瘤（“MM”）等治疗。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/ZDU0NTAxYWI0ZTVjNGI1NGI3MDRmODY1NTI2NDgyOTg3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ZDU0NTAxYWI0ZTVjNGI1NGI3MDRmODY1NTI2NDgyOTg3.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1975070","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696","HK0000306685.HKD","HK0000320223.HKD","HK0000165453.HKD","HK0000320264.USD","HK0000306701.USD","BK1161"],"gpt_icon":0},{"id":"1187934226","title":"复宏汉霖HLX15-SC治疗多发性骨髓瘤新药临床试验申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1187934226","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187934226?lang=zh_cn&edition=full","pubTime":"2026-02-12 16:51","pubTimestamp":1770886276,"startTime":"0","endTime":"0","summary":"复宏汉霖（股票代码：02696）近日宣布，其自主研发的HLX15-SC用于治疗多发性骨髓瘤的新药临床试验（IND）申请，已正式获得中国国家药品监督管理局（NMPA）的批准。\n这一进展标志着该候选药物在临床开发道路上迈出了关键一步，为后续的人体安全性及有效性研究奠定了基础。多发性骨髓瘤作为一种恶性血液肿瘤，其治疗领域存在显著的未满足临床需求，HLX15-SC的研发进展因此备受关注。\n公司表示，将依据相关法律法规和要求，尽快推进该药物的临床试验工作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000320223.HKD","HK0000165453.HKD","02696","HK0000306685.HKD","HK0000320264.USD","HK0000306701.USD","BK1161"],"gpt_icon":0},{"id":"2611297663","title":"复宏汉霖02月12日获主力加仓69.1万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2611297663","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611297663?lang=zh_cn&edition=full","pubTime":"2026-02-12 16:15","pubTimestamp":1770884141,"startTime":"0","endTime":"0","summary":"02月12日, 复宏汉霖股价涨0.84%，报收71.95元，成交金额5769.7万元，换手率0.23%，振幅3.71%，量比0.24。复宏汉霖今日主力资金净流入69.1万元，连续7日净流入，上一交易日主力净流入374.9万元。该股近5个交易日上涨19.22%，主力资金累计净流入4101.3万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流出601.7万元，其中净流出天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212161845a49b8dc1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212161845a49b8dc1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000165453.HKD","BK1161","HK0000320264.USD","02696","HK0000306701.USD","HK0000306685.HKD","HK0000320223.HKD"],"gpt_icon":0},{"id":"2610187987","title":"复宏汉霖(02696)：注射用HLX43联合HLX07或汉斯状®在晚期或转移性结直肠癌患者中开展的1b/2期临床研究于中国境内完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2610187987","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610187987?lang=zh_cn&edition=full","pubTime":"2026-02-11 17:02","pubTimestamp":1770800537,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖(02696)发布公告，近日，注射用HLX43(靶向PD-L1抗体偶联药物)(“HLX43”)联 合 HLX07(重组抗EGFR人源化单克隆抗体注射液)(“ HLX07”)或汉斯状®(斯鲁利单抗注射液)(“汉斯状®”)在晚期或转移性结直肠癌患者中开展的1b/2期临床研究于中国境内(不包括中国港澳台地区，下同)完成首例患者给药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1404189.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"复宏汉霖(02696)：注射用HLX43联合HLX07或汉斯状®在晚期或转移性结直肠癌患者中开展的1b/2期临床研究于中国境内完成首例患者给药","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000320264.USD","BK1161","02696","HK0000306685.HKD","HK0000320223.HKD","HK0000165453.HKD","HK0000306701.USD"],"gpt_icon":0},{"id":"2610348987","title":"每日卖空追踪 | 复宏汉霖 02月11日卖空量成交2.67万股，卖空比例为0.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610348987","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610348987?lang=zh_cn&edition=full","pubTime":"2026-02-11 16:30","pubTimestamp":1770798636,"startTime":"0","endTime":"0","summary":"复宏汉霖北京时间02月11日，跌0.83%，卖空量成交2.67万股，较上一交易日减少84.33%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211163450a4973188&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211163450a4973188&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000165453.HKD","02696","BK1161","HK0000306685.HKD","HK0000320264.USD","HK0000306701.USD","HK0000320223.HKD"],"gpt_icon":0},{"id":"2610878059","title":"医药生物行业周报（2月第1周）：初代IO走出BD新路","url":"https://stock-news.laohu8.com/highlight/detail?id=2610878059","media":"世纪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610878059?lang=zh_cn&edition=full","pubTime":"2026-02-10 20:06","pubTimestamp":1770725197,"startTime":"0","endTime":"0","summary":"初代IO走出BD新路。IO疗法是国内创新药最卷方向，截止25年已有23个PD-1产品上市，不同于去年MNC争夺的二代IO资产，斯鲁利单抗作为初代IO，凭借临床差异化布局，在小细胞肺癌领域另辟蹊径，单一区域授权并保留MAH责任，真正做到了深度挖掘创新药资产价值，利用国内研发优势，以时间换价值，树立了创新药内卷时代的BD新标杆。我们建议持续关注在BD方向有新意的创新药公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210200640a4938b94&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210200640a4938b94&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000306701.USD","HK0000320264.USD","02696","BK1161","HK0000320223.HKD","HK0000306685.HKD","HK0000165453.HKD"],"gpt_icon":0},{"id":"2610769203","title":"多重利好叠加，复宏汉霖续涨超8%，6日连涨30%走出反转行情","url":"https://stock-news.laohu8.com/highlight/detail?id=2610769203","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610769203?lang=zh_cn&edition=full","pubTime":"2026-02-10 11:55","pubTimestamp":1770695749,"startTime":"0","endTime":"0","summary":"2月10日，复宏汉霖再度拉升涨超8%，6日连涨高达30%，并且走出反转行情，现报72.7港元，总市值396亿港元。消息上，复宏汉霖日前宣布完成H股全流通，扩大流通规模助力全球化战略，释放长期投资价值。卫材将向复宏汉霖支付7500万美元的首付款，最高可达8001万美元的监管里程碑付款，以及最高可达2.333亿美元的销售里程碑付款；复宏汉霖还将根据产品销售额获得两位数百分比的特许权使用费。","market":"sh","thumbnail":"http://imgcloud.jrjimg.cn/2026/02/cms_20260210115549321.jpg","type":0,"news_type":0,"thumbnails":["http://imgcloud.jrjimg.cn/2026/02/cms_20260210115549321.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/02/10115555757203.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","02696","HK0000320223.HKD","HK0000165453.HKD","HK0000320264.USD","HK0000306685.HKD","HK0000306701.USD"],"gpt_icon":0},{"id":"2610691488","title":"港股异动 | 复宏汉霖(02696)再涨超6% 月内涨超24% 公司将斯鲁利单抗日本权益授权给卫材","url":"https://stock-news.laohu8.com/highlight/detail?id=2610691488","media":"智通财经","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610691488?lang=zh_cn&edition=full","pubTime":"2026-02-10 11:21","pubTimestamp":1770693699,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，复宏汉霖再涨超6%，月内累计涨幅已超24%。消息面上，2月5日，卫材株式会社与复宏汉霖联合宣布，双方已就抗PD-1抗体斯鲁利单抗在日本市场达成独家商业化协议，并签订联合独家开发与生产许可协议。卫材将向复宏汉霖支付7500万美元的首付款，最高可达8001万美元的监管里程碑付款，以及最高可达2.333亿美元的销售里程碑付款；复宏汉霖还将根据产品销售额获得两位数百分比的特许权使用费。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1403541.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000306685.HKD","BK4588","HK0000320264.USD","BK4585","HK0000306701.USD","HK0000320223.HKD","VT","02696","HK0000165453.HKD","BK1161","VXUS"],"gpt_icon":0},{"id":"2610268695","title":"恒生医疗保健指数升2.17%  医药板块普遍拉升 机构持续看好中国创新药出海的产业趋势","url":"https://stock-news.laohu8.com/highlight/detail?id=2610268695","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610268695?lang=zh_cn&edition=full","pubTime":"2026-02-10 09:59","pubTimestamp":1770688793,"startTime":"0","endTime":"0","summary":"2月8日，信达生物宣布与礼来制药达成战略合作，携手推进肿瘤及免疫领域创新药物的全球研发。2026年，继续看好中国创新药出海的产业趋势，继续重点跟踪ADC、双抗、小核酸、减肥药等核心优势赛道的投资机会，期待JPM大会、ASCO等带来数据更新和BD催化。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"8f73ea90e21e93e4b02cf2f8986a9c30","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1974845","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995","LU0634319403.HKD","LU0516422366.SGD","BK1587","LU0823426308.USD","LU0196878994.USD","LU0140636845.USD","02696","06978","LU0359202008.SGD","LU1969619763.USD","02268","LU2039709279.SGD","02269","LU1961090484.USD","LU1720050803.USD","BK1161","LU2476274308.USD","09939","LU0417516902.SGD","159992","03347","02162","01548","LU0502904849.HKD","LU2242644610.SGD","LU2488822045.USD","LU2045819591.USD","09688","LU0348825331.USD","LU0572944931.SGD","IE00B5MMRT66.SGD","LU0181495838.USD","LU0417516738.SGD","LU0516423174.USD","02359","01877","01801","159938","06990","LU0051755006.USD","09926","159506","LU0856984785.SGD","LU0043850808.USD","HK0000306701.USD","LU1046422090.SGD","LU2476274720.SGD","LU1688375341.USD","09969"],"gpt_icon":1},{"id":"2610586665","title":"每日卖空追踪 | 复宏汉霖 02月09日卖空量成交2.62万股，卖空比例为2.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610586665","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610586665?lang=zh_cn&edition=full","pubTime":"2026-02-09 16:30","pubTimestamp":1770625833,"startTime":"0","endTime":"0","summary":"复宏汉霖北京时间02月09日，涨5.09%，卖空量成交2.62万股，较上一交易日减少92.98%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260209163909a6e55171&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260209163909a6e55171&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000165453.HKD","HK0000306685.HKD","HK0000320264.USD","HK0000306701.USD","02696","BK1161","HK0000320223.HKD"],"gpt_icon":0},{"id":"2610568695","title":"高盛：今年内地医疗板块更依赖数据及盈利能见度 看好CDMO企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2610568695","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610568695?lang=zh_cn&edition=full","pubTime":"2026-02-09 14:08","pubTimestamp":1770617323,"startTime":"0","endTime":"0","summary":"今年要获得超越行业的回报，更依赖于关键数据公布、实际成交，以及盈利兑现或转折点的能见度。该行对医疗器械板块维持中性看法，虽然行业已触底，但需时逐步复苏；推荐买时代天使及威高股份。医疗服务板块方面，该行仍持相对谨慎态度，因成本控制措施的持续影响，以及疲弱的消费周期；下调海吉亚医疗评级至“中性”。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1403066.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0708995583.HKD","BK1161","BK1589","02359","BK4139","HK0000165453.HKD","LU0196878994.USD","BK1576","06990","LU2488822045.USD","159891","CDMO","LU2125910500.SGD","03692","HK0000320223.HKD","02696","LU1046422090.SGD","HK0000306685.HKD","02268","HK0000320264.USD","LU2045819591.USD","HK0000306701.USD","BK1141","LU0320764599.SGD","SG9999014674.SGD","LU2242644610.SGD","BK1191","LU0052750758.USD","BK1583"],"gpt_icon":0},{"id":"2610504112","title":"复宏汉霖盘中异动 股价大涨5.02%报67.000港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2610504112","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610504112?lang=zh_cn&edition=full","pubTime":"2026-02-09 09:33","pubTimestamp":1770600817,"startTime":"0","endTime":"0","summary":"2026年02月09日早盘09时33分，复宏汉霖股票出现异动，股价急速拉升5.02%。截至发稿，该股报67.000港元/股，成交量15.7万股，换手率0.05%，振幅6.11%。资金方面，该股资金流入406.631万港元，流出71.0955万港元。复宏汉霖股票所在的生物技术行业中，整体涨幅为1.54%。其相关个股中，歌礼制药-B、康诺亚-B、奥星生命科技涨幅较大，振幅较大的相关个股有复宏汉霖、映恩生物-B、歌礼制药-B，振幅分别为6.11%、5.90%、5.66%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260209093337a6e3ca94&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260209093337a6e3ca94&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02696","HK0000306701.USD","HK0000165453.HKD","HK0000306685.HKD","HK0000320223.HKD","BK1161","HK0000320264.USD"],"gpt_icon":0},{"id":"2609752625","title":"复宏汉霖PD-1新药“出海”日本 最早将于2028年产生销售提成","url":"https://stock-news.laohu8.com/highlight/detail?id=2609752625","media":"证券日报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609752625?lang=zh_cn&edition=full","pubTime":"2026-02-08 17:39","pubTimestamp":1770543568,"startTime":"0","endTime":"0","summary":"日前，上海复宏汉霖生物技术股份有限公司（以下简称“复宏汉霖”）与卫材株式会社（以下简称“卫材”）共同宣布，双方已就抗PD-1单抗汉斯状（斯鲁利单抗，以下简称“PD-1新药”）在日本达成一项独家商业化及共同独家开发与生产许可协议。汉斯状是复宏汉霖自主研发的一款PD-1新药。根据协议，卫材将获得汉斯状在日本的独家商业化权益。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602083644840016.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1169590202.USD","HK0000306701.USD","HK0000320223.HKD","HK0000306685.HKD","02696","HK0000165453.HKD","PD","BK4023","LU1169589451.USD","BK1161","HK0000320264.USD"],"gpt_icon":0},{"id":"2609527492","title":"生物类似药，卷土重来","url":"https://stock-news.laohu8.com/highlight/detail?id=2609527492","media":"医前沿","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609527492?lang=zh_cn&edition=full","pubTime":"2026-02-07 20:31","pubTimestamp":1770467497,"startTime":"0","endTime":"0","summary":"在当前创新药高举高打的热潮下，生物类似药似乎在角落中再次萌芽，迎来了新的生机。粗略检索CDE受理品种信息，国内生物药3.3类生物类似药申报数量达到了26项，自2025年以来增速显著。这些都是生物类似药研发的主流企业，都有多款产品获批上市。成都康弘通过布局IL-4R和PD-1两项爆款生物类似药，快速重启生物新药研发，与两款双抗双毒素ADC创新管线交相辉映，在创新药的不确定性中寻找确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260207204301a4881bd7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260207204301a4881bd7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1589","LU0455707207.USD","LU2097828631.EUR","BK1583","02696","LU2242644610.SGD","LU2097828557.USD","LU2488822045.USD","01093","LU2097828474.EUR","BK1161","LU2328871848.SGD","LU1969619763.USD","LU2097828805.USD","LU0502904849.HKD","HK0000165453.HKD","01801","LU2097828714.EUR"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.027},{"period":"1month","weight":0.1681},{"period":"3month","weight":0.1324},{"period":"6month","weight":-0.1347},{"period":"1year","weight":2.5244},{"period":"ytd","weight":0.2664}],"compareEarnings":[{"period":"1week","weight":-0.0058},{"period":"1month","weight":-0.0065},{"period":"3month","weight":0.0473},{"period":"6month","weight":0.0424},{"period":"1year","weight":0.1699},{"period":"ytd","weight":0.0305}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海复宏汉霖生物技术股份有限公司是一家主要从事生物制药研发、生物制药服务及生物制药生产与销售的中国公司。该公司的主要产品包括汉曲优（注射用曲妥珠单抗）、汉奈佳（马来酸奈拉替尼片）、汉斯状（斯鲁利单抗注射液）、汉利康（利妥昔单抗注射液）、汉达远（阿达木单抗注射液）、汉贝泰（贝伐珠单抗注射液）等。该公司的产品主要应用于乳腺癌辅助治疗、转移性乳腺癌及转移性胃癌治疗、转移性非鳞状非小细胞肺癌、多关节型幼年特发性关节炎治疗等。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.044394},{"month":2,"riseRate":0.714286,"avgChangeRate":0.130659},{"month":3,"riseRate":0.5,"avgChangeRate":-0.016995},{"month":4,"riseRate":0.833333,"avgChangeRate":0.128587},{"month":5,"riseRate":0.5,"avgChangeRate":-0.024483},{"month":6,"riseRate":0.666667,"avgChangeRate":0.109389},{"month":7,"riseRate":0.5,"avgChangeRate":0.069459},{"month":8,"riseRate":0.5,"avgChangeRate":-0.024213},{"month":9,"riseRate":0,"avgChangeRate":-0.127435},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.025526},{"month":11,"riseRate":0.571429,"avgChangeRate":0.058675},{"month":12,"riseRate":0.714286,"avgChangeRate":-0.023816}],"exchange":"SEHK","name":"复宏汉霖","nameEN":"HENLIUS"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复宏汉霖(02696)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复宏汉霖,02696,复宏汉霖股票,复宏汉霖股票老虎,复宏汉霖股票老虎国际,复宏汉霖行情,复宏汉霖股票行情,复宏汉霖股价,复宏汉霖股市,复宏汉霖股票价格,复宏汉霖股票交易,复宏汉霖股票购买,复宏汉霖股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复宏汉霖(02696)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}